Pharmaceuticals Market Structure

Pharmaceuticals Market Structure

Please do your best to produce a quality paper about an economic analysis of pharmaceuticals by 10am. 12/7/2020

“Your written report should begin with an introduction that motivates the subsequent analysis: a. What is the economic problem? b. What are the antitrust issues? c. What do you plan to do in your analysis? Each subsequent section should move the reader forward in his or her understanding. You are economists. Use your economic tools – supply and demand, theory of the firm, analysis of market structures, and analysis of market failure. Use what you need to develop your analysis. Your focus should be on the antitrust law and economics problem(s) that you are addressing. You must provide thorough explanations. Pretend that you are writing for an intelligent reader with very little training in Economics. You may not plagiarize someone else’s work. You may, however, consult any materials that you can find: textbooks, journal articles, news media accounts, and so on. You should cite your sources – for formatting, please look at the draft chapters. I want footnotes, not endnotes. I want references listed at the end of your report.”
Outline:

The topic I have selected for this project will be analyzing the market structure of pharmaceuticals. The project will be divided into eight different sections including the introduction and conclusion. The introduction will motivate the subsequent analysis of what is the economic problem, the antitrust issues, and the pharmaceutical market structure. The project will be split into five parts, introduction, economic problems, antitrust issues, and an analysis of pharmaceutical market structure which will be the main component of this project. For this project I have collected sixteen sources in total. Two sources each for the economic problems of pharmaceutical, antitrust issue of pharmaceuticals, size of pharmaceuticals firms, pharmaceuticals sales, pharmaceuticals production facilities, pharmaceuticals major products, pharmaceuticals marketing, and of the competitive environment of pharmaceuticals. Overall, the basic layout of the project currently will be as follows:

Note: In analyzing market structure, I am interested in the sizes of the firms, their

sales, production facilities, major products, marketing methods, and an

assessment of the competitive environment.

Please cite use footnotes and include a bibliography

-Introduction (Part 1)

-Economic problems (Part 2)

-Antitrust issues (Part 3)

-Analysis of pharmaceutical market structure (Part 4)

-Size of firms

-Sales

-Production facilities

-Major products

-Marketing methods

-Assessment of the competitive environment

-Conclusion (Part 5)

Feel free to use or replace the sources I provided.

Bibliography:

SubbaNarasimha, P. N., Ahmad, S., & Mallya, S. N. (2003). Technological knowledge and firm performance of pharmaceutical firms. Journal of Intellectual Capital.

Pradhan, J. P. (2003). Liberalization, firm size and R&D performance: A firm level study of Indian pharmaceutical industry. Journal of Indian school of political economy, 14(4), 647-666.

Rugman, A. M., & Brain, C. (2004). Regional strategies of multinational pharmaceutical firms. In Management International Review (pp. 7-26). Gabler Verlag, Wiesbaden.

John, A. G., Francis, A. I., & Innocent, I. (2012). Improving sales performance through sales force motivation strategies: A study of pharmaceutical firms in Nigeria. Int. J. Buss. Mgt. Eco. Res, 3(5), 620-626.

Habib, M. A., & Alam, M. Z. (2011). Business analysis of pharmaceutical firms in Bangladesh: problems and prospects. Journal of Business and Technology (Dhaka), 6(1), 61-77.

Chaturvedi, K., Chataway, J., & Wield, D. (2007). Policy, markets and knowledge: Strategic synergies in Indian pharmaceutical firms. Technology Analysis & Strategic Management, 19(5), 565-588.

Galambos, L., & Sturchio, J. L. (1998). Pharmaceutical firms and the transition to biotechnology: A study in strategic innovation. The Business History Review, 250-278.

Liebenau, J. (1984). Industrial R & D in pharmaceutical firms in the early twentieth century. Business History, 26(3), 329-346.

Herrmann, A. M. (2008). One Political Economy, One Competitive Strategy?: Comparing Pharmaceutical Firms in Germany, Italy, and the UK. Oxford University Press.

Mohammadzadeh, M., Aarabi, S. M., & Salamzadeh, J. (2013). Organizational performance, Marketing strategy, and Financial strategic alignment: an empirical study on Iranian pharmaceutical firms. DARU Journal of Pharmaceutical Sciences, 21(1), 65.

Roberts, P. W. (1999). Product innovation, product–market competition and persistent profitability in the US pharmaceutical industry. Strategic management journal, 20(7), 655-670.

Morton, F. S. (1996). The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules (No. w5717). National Bureau of Economic Research.

Levy, R. (1999). The pharmaceutical industry: a discussion of competitive and antitrust issues in an environment of change. DIANE Publishing.

Danzon, P. M. (2014). Competition and Antitrust Issues in the Pharmaceutical Industry. CRC America Latina-Centro Regional de Competencia para America Latina.

Malik, M. S., & Kanwal, L. (2018). Impact of corporate social responsibility disclosure on financial performance: case study of listed pharmaceutical firms of Pakistan. Journal of Business Ethics, 150(1), 69-78.

Karamehic, J., Ridic, O., Ridic, G., Jukic, T., Coric, J., Subasic, D., … & Masic, I. (2013). Financial aspects and the future of the pharmaceutical industry in the United States of America. Materia socio-medica, 25(4), 286.